Canadian application, no grantCanada
N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
CA 2472204 A1 · Owner: Astrazeneca Ab · Inventors: Baxter, Andrew; Roberts, Bryan; Johnson, Timothy
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides N-pyrazinyl-phenylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 14, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 14, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 14, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJanuary 14, 2003
GrantedNo grant recorded
Term endedJanuary 14, 2023
Patent numberCA 2472204 A1
Classification (IPC)C07D241/22 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.